$AI

Hyten John E. sold (to issuer) $23K of AI

Hyten John E. sold (to issuer) 2,500 shares of C3.ai, Inc. (AI) at $9.14 on 2026-07-15.

Original reporting
SEC EDGAR · Hyten John E.
Published Jul 16, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AI
Neutral
medium confidence
Mentioned
$AI
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AINeutralLow
01

Why it matters

The newest fact is the specific insider sale size, price, and post-transaction holdings, which can marginally influence sentiment but does not, by itself, change fundamentals.

02

Market read

Traders may note the insider sale as a small sentiment datapoint, but there is no accompanying operational, financial, or regulatory catalyst in the text.

03

What to watch

The filing does not state the reason for the sale, and the absence of a disclosed 10b5-1 plan does not prove insider concern; it only removes one common explanation.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-07-16 for a sale dated 2026-07-15.

Background

The article is a SEC Form 4 insider transaction disclosure for C3.ai, Inc. (AI).

Company-level read

Ticker impact

$AINeutralMedium confidence
Context

C3.ai director Hyten John E. sold 2,500 shares to the issuer at $9.14/share on 2026-07-15, per a new Form 4 filed 2026-07-16.

Expected impact

Likely limited near-term impact; any effect would be small and short-lived unless followed by additional disclosures.

Evidence & confidence

Form 4 insider sales are common and often pre-planned; here the filing explicitly notes no pre-arranged 10b5-1 plan, but the transaction is still a modest, single-director sale with no accompanying company event in the text.

Market effects

Minimal; no sector-wide signal is provided beyond an isolated insider transaction at an AI software name.

None indicated.

None indicated.

Counterpoint

The sale is to the issuer (buyback participation or similar) and may reflect liquidity or plan mechanics rather than bearish expectations.

Key entities

  • C3.ai, Inc.

    Company whose director insider transaction is disclosed on Form 4.

  • Hyten John E.

    Director who sold 2,500 shares to the issuer at $9.14/share.

Related articles

$AIMed

Trump Family Pockets Half A Billion As Trump-Backed Crypto Firm Moves To Sell Only Revenue-Generating Business

The Wall Street Journal reports Nasdaq-listed AI Financial (formerly Alt5 Sigma) is in talks to sell its only revenue-generating payments subsidiary to Tokyo-based Perpetuals.com for up to $15 million. The unit generated about $25 million revenue in 2024. AI Financial’s losses followed World Liberty’s August 2025 WLFI token purchase and WLFI’s ~70% decline, with AI Financial reporting a $271 million quarterly loss.

$AIMedAI 9/10

C3.ai Q4 2026 Earnings Call Transcript - C3.ai (NYSE:AI)

C3.ai held its Q4 earnings call, reporting total revenue of $51.6 million, with subscription revenue 94% of the total. The company said it cut headcount about 35% and expects ~$135 million in annual operating cost savings. CEO Tom Siebel cited poor sales execution and plans to expand its target accounts. FY2027 guidance calls for $210–$240 million revenue and non-GAAP operating loss of $128–$160 million.

$AIHighAI 9/10

Live: Will C3.ai Beat Q4 Earnings After the Bell Tonight?

C3.ai (AI) reports Q4 fiscal 2026 results after the close. The company is focused on revenue within guidance ($48.0M–$52.0M), improving GAAP gross margin from 17% (down from 59% a year earlier), and expanding federal bookings, which rose 134% YoY to 55% of total bookings. Wall Street has 6 sell and 7 hold ratings; average target is $8.82 vs. $10.51.

$AIMedAI 8/10

Wall Street Has a Consensus on This AI Stock. The Consensus Is Dead Wrong.

The article argues that Wall Street’s consensus on C3.ai (AI) is inconsistent and may not reflect deteriorating fundamentals. It cites a hold consensus from 12 analysts with an average price target near $17 versus a stock price around $9.50. For fiscal Q1 2026 ended July 31, C3.ai reported about $50M revenue, missed guidance, posted a $0.40 loss per share vs $0.30 estimate, and guided continued pressure.

$AIMedAI 9/10

Thomas Siebel Is Back as C3.ai CEO. Will This Help the Stock Rebound?

C3.ai shares are down 59% over 12 months as the company’s sales have declined, despite having 100+ enterprise AI turnkey solutions. After CEO/founder Thomas Siebel stepped down in 2024 for health reasons and Stephen Ehikian took over Sept. 1, 2025, C3.ai reported preliminary Q4 revenue of $51.6M vs. $108.7M a year earlier. The company says Siebel returned as CEO May 8.